Tracey Roizman

The spatial distribution of CD103+CD8+ tissue-resident memory T cells is a prognostic biomarker for non-small cell lung cancer, according to the results of a recent cohort study. Tissue-resident memory T cells (TRM) are a special population of immune cells that reside in solid[spacer height=”10px”]tumors and their microenvironment. Although emerging evidence has linked these cells to[spacer...

Serum levels of 8-hydroxy-deoxyguanosine were positively correlated with ionizing radiation in non-small cell lung cancer, with possible prognostic significance in the squamous pathology subgroup in an observational study. Ionizing radiation is associated with DNA damage, which can be direct or indirect, as with the production of reactive oxygen species (ROS). The most common ROS-induced base...

The long non-coding RNA LINC02159 promotes non-small cell lung cancer progression through ALYREF/YAP1 signaling, according to the results of a recent cell culture study. Lung cancer is the leading cause of cancer-related deaths globally. Long non-coding RNAs (lncRNAs) have recently emerged as key regulators in cancer development and progression, including non-small cell lung cancer (NSCLC),...

Amivantamab plus lazertinib shows durable clinical activity in osimertinib-relapsed, epidermal growth factor receptor-mutated advanced non-small cell lung cancer in a phase I study. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), is the current standard-of-care treatment for EGFR-mutated non-small cell lung cancer (NSCLC). However, resistance is common, and there are no...

Circulating tumor DNA response to pembrolizumab can identify patients with molecular disease progression needing treatment intensification, according to the results of a phase II/III clinical trial. Circulating tumor DNA (ctDNA) has demonstrated promise in identifying primary resistance to immunotherapy. Concerning non-small cell lung cancer (NSCLC), where pembrolizumab and combination pembrolizumab–carboplatin–taxane/pemetrexed are the first-line options, it...

A recent literature review identifies promising therapeutic agents that have shifted the non-small cell lung cancer treatment paradigm. Lung cancer is the leading cause of cancer mortality worldwide. Research is rapidly evolving regarding the treatment of non-small cell lung cancer (NSCLC) with biomarker-driven targeted therapy and immunotherapy using checkpoint inhibitors.  A review of phase III...

Aquaporins are involved in the normal physiology of the skin, and the dysregulation of aquaporins is implicated in different skin disorders, serving as potential therapeutic targets. Aquaporins (AQPs) are membrane channel proteins that allow the movement of small neutral solutes and water, playing an important role in the skin’s barrier function. The altered skin barrier...

A phase 1–2 clinical trial found that adagrasib combined with cetuximab in patients with KRAS G12C mutations can increase progression-free survival and overall survival in refractory colorectal cancer patients. There is a pressing need for effective treatments for metastatic colorectal cancer, particularly for patients with the KRAS G12C mutation, a kind of colorectal cancer that...

A phase 3 clinical trial confirms that combination therapy with trifluridine–tipiracil plus bevacizumab is associated with better clinical outcomes in refractory colorectal cancer cases than trifluridine–tipiracil monotherapy. First-line and second-line treatment of colorectal cancer includes chemotherapy with fluorouracil-based agents (oxaliplatin and irinotecan) along with newer vascular endothelial growth factor (VEGF)-based therapy (mainly bevacizumab) and epidermal...